Juliet Singh
Chief Executive Officer at Transdel Pharmaceuticals Holdings, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Mark Baum | M | 51 | 18 years | |
| Jeffrey J. Abrams | M | 76 |
Transdel Pharmaceuticals Holdings, Inc.
 Transdel Pharmaceuticals Holdings, Inc. Other Metals/MineralsNon-Energy Minerals Part of Harrow, Inc., Transdel Pharmaceuticals Holdings, Inc. is a company that specializes in the offices of other holding companies. The company is based in Escondido, CA. Juliet Singh has been the CEO of the company since 2005. | 26 years |
| Balbir S. Brar | M | 87 |
Transdel Pharmaceuticals Holdings, Inc.
Transdel Pharmaceuticals Holdings, Inc. Other Metals/MineralsNon-Energy Minerals Part of Harrow, Inc., Transdel Pharmaceuticals Holdings, Inc. is a company that specializes in the offices of other holding companies. The company is based in Escondido, CA. Juliet Singh has been the CEO of the company since 2005. | 2 years |
| John T. Lomoro | M | 54 |
Transdel Pharmaceuticals Holdings, Inc.
Transdel Pharmaceuticals Holdings, Inc. Other Metals/MineralsNon-Energy Minerals Part of Harrow, Inc., Transdel Pharmaceuticals Holdings, Inc. is a company that specializes in the offices of other holding companies. The company is based in Escondido, CA. Juliet Singh has been the CEO of the company since 2005. | 17 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Douglas Ingram | M | 61 | 19 years | |
| Robert J. Kammer | M | 74 | 16 years | |
| David Pyott | M | 70 | 17 years | |
| Aimee Weisner | F | 55 | 4 years | |
| Michael R. Gallagher | M | 77 | - | |
| Eric Brandt | M | 62 | 6 years | |
| Rolf Harms | M | - | - | |
| J. Michael Judy | M | - | 8 years | |
| William Humphries | M | 57 | 8 years | |
| James R. Largent | M | 74 | 6 years | |
| Robert T. Joseph | M | 47 | 2 years | |
| Julian Gangolli | M | 66 | 17 years | |
| John Gainor | M | - | 5 years | |
| Ted Williams | M | - |
Collateral Therapeutics, Inc.
 Collateral Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Collateral Therapeutics, Inc. focuses on the discovery and development of non-surgical gene therapy product candidates for the potential treatment of cardiovascular diseases including: coronary artery disease; peripheral vascular disease; restenosis; congestive heart failure and heart attack. The company's core technology is centered on methods of cardiovascular gene therapy; a portfolio of therapeutic genes and gene delivery vectors. Its portfolio includes human genes in the Fibroblast Growth Factor (FGF) and Vascular Endothelial Growth Factor (VEGF) gene families to be used in investigational gene therapy product candidates. The company is headquartered in San Diego, CA. | 3 years |
| Anthony Andrasfay | M | - |
Collateral Therapeutics, Inc.
Collateral Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Collateral Therapeutics, Inc. focuses on the discovery and development of non-surgical gene therapy product candidates for the potential treatment of cardiovascular diseases including: coronary artery disease; peripheral vascular disease; restenosis; congestive heart failure and heart attack. The company's core technology is centered on methods of cardiovascular gene therapy; a portfolio of therapeutic genes and gene delivery vectors. Its portfolio includes human genes in the Fibroblast Growth Factor (FGF) and Vascular Endothelial Growth Factor (VEGF) gene families to be used in investigational gene therapy product candidates. The company is headquartered in San Diego, CA. | 4 years |
| Patricia L. Novak | M | - |
Collateral Therapeutics, Inc.
Collateral Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Collateral Therapeutics, Inc. focuses on the discovery and development of non-surgical gene therapy product candidates for the potential treatment of cardiovascular diseases including: coronary artery disease; peripheral vascular disease; restenosis; congestive heart failure and heart attack. The company's core technology is centered on methods of cardiovascular gene therapy; a portfolio of therapeutic genes and gene delivery vectors. Its portfolio includes human genes in the Fibroblast Growth Factor (FGF) and Vascular Endothelial Growth Factor (VEGF) gene families to be used in investigational gene therapy product candidates. The company is headquartered in San Diego, CA. | 6 years |
| Albert Moyer | M | 80 | 3 years | |
| Daniel P. Cafaro | M | 67 | 15 years | |
| Dennis Podlesak | M | 66 | 4 years | |
| Holger Heidrich | M | 71 | 4 years | |
| Lynn Swann | M | 72 | 3 years | |
| Terry M. Nida | M | - | 1 years | |
| Vicente J. Anido | M | 71 | 3 years | |
| Harry Leonhardt | M | 67 | 6 years | |
| Anthony Thornley | M | 77 | 4 years | |
| Karen Osar | F | 74 | 7 years | |
| Leonard R. Borrmann | M | 66 | 14 years | |
| Scott Whitcup | M | 64 | 15 years | |
| Catherine Turkel | M | 63 | 17 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 33 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Juliet Singh
- Personal Network
